[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642972":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":55,"studyPopulation":44,"armGroups":56,"interventions":73,"overallOfficials":83,"centralContacts":87,"locations":44,"responsibleParty":96,"collaborators":100,"id":108,"slug":44,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":109,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":44,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":130,"whyStopped":44,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":44},{"fullName":5,"class":6},"The Affiliated Hospital Of Guizhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":44},[9],{"measure":10,"description":11,"timeFrame":12},"Migraine attack frequency (days \u002F month)","Change from baseline in the mean number of migraine days per month within 90 days, at the 90-day visit, and at the 180-day visit after randomization.",":At baseline,within 90 days, 90-day, 180-day after treatment",[14,18,22,25,28,32,35,38,41],{"measure":15,"description":16,"timeFrame":17},"Migraine attack frequency (times \u002F month)","Change from baseline in the mean number of migraine attacks per month within 90 days, at the 90-day visit, and at the 180-day visit after randomization.","At baseline, within 90 days, 90-day, 180-day after treatment",{"measure":19,"description":20,"timeFrame":21},"Total headache frequency (days \u002F month)","Change from baseline in the mean number of all headache days per month within 90 days after randomization.","At baseline, within 90 days after treatment",{"measure":23,"description":24,"timeFrame":17},"Migraine medication use frequency (days \u002F month)","Change from baseline in the mean number of migraine medication use days per month within 90 days, at the 90-day visit, and at the 180-day visit after randomization.",{"measure":26,"description":27,"timeFrame":17},"Proportion of ≥50% reduction in migraine days (days\u002Fmonth)","Proportion of participants with at least a 50% reduction from baseline in the mean number of migraine days per month within 90 days, at the 90-day visit, and at the 180-day visit after randomization.",{"measure":29,"description":30,"timeFrame":31},"Numerical Rating Scale for migraine pain severity (NRS) (score\u002Fmonth)","Change from baseline in the mean monthly Migraine Pain Severity Score (NRS) within 90 days and within 180 days after randomization.","At baseline, within 90 days, 180 days after treatment",{"measure":33,"description":34,"timeFrame":31},"Migraine Disability Assessment Questionnaire (MIDAS) (score\u002Fmonth)","Change from baseline in the mean monthly Migraine Disability Assessment Score (MIDAS) within 90 days and within 180 days after randomization.",{"measure":36,"description":37,"timeFrame":31},"Clinical Global Impression Scale (CGI) (score\u002Fmonth)","Change from baseline in the mean monthly Clinical Global Impression (CGI) Scale score within 90 days and within 180 days after randomization.",{"measure":39,"description":40,"timeFrame":31},"Headache Impact Test (HIT-6) (score\u002Fmonth)","Change from baseline in the mean monthly Headache Impact Test-6 (HIT-6) score within 90 days and within 180 days after randomization.",{"measure":42,"description":43,"timeFrame":31},"Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) (score\u002Fmonth)","Change from baseline in the mean monthly Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1) score within 90 days and within 180 days after randomization.",null,{"allocation":46,"interventionModel":47,"interventionModelDescription":48,"primaryPurpose":49,"observationalModel":44,"timePerspective":44,"maskingInfo":50},"RANDOMIZED","PARALLEL","randomized controlled","TREATMENT",{"masking":51,"maskingDescription":44,"whoMasked":52},"DOUBLE",[53,54],"PARTICIPANT","OUTCOMES_ASSESSOR","This study is a multicenter, prospective, double-blind, multi-arm, randomized controlled trial that investigates whether middle meningeal artery embolization is superior to current standard pharmacotherapy for migraine. The main objectives of the study are to explore whether middle meningeal artery embolization can reduce migraine patients' dependence on migraine medications and to assess the safety of middle meningeal artery embolization with coils.This study will enroll 150 subjects with a long history of headache from multiple clinical centers, who will be randomly assigned using a stratified randomization method via computer and web-based software. Stratified randomization will be performed according to study centers (different sub-centers). Subjects will be randomly allocated in a 1:1:1 ratio to the unilateral embolization group, bilateral embolization group, or conventional pharmacotherapy group (hereinafter referred to as the \"control group\"), with 50 subjects in each group. The unilateral embolization group will receive unilateral MMA interventional embolization plus conventional pharmacotherapy, the bilateral embolization group will receive bilateral MMA interventional embolization plus conventional pharmacotherapy, and the control group will receive only conventional standard pharmacotherapy. Baseline data prior to randomization and data on primary and secondary endpoint scores will be collected for all enrolled subjects. Regular follow-up will be conducted to evaluate the recovery of headache.",[57,64,68],{"label":58,"type":59,"description":60,"interventionNames":61},"Unilateral Middle Meningeal Artery Embolization + Standard Pharmacotherapy","EXPERIMENTAL","Subjects in this arm will receive unilateral middle meningeal artery embolization with coils plus conventional standard pharmacotherapy for migraine.",[62,63],"Procedure: Middle meningeal artery embolization","Drug: Conventional standard pharmacotherapy for migraine",{"label":65,"type":59,"description":66,"interventionNames":67},"Bilateral Middle Meningeal Artery Embolization + Standard Pharmacotherapy","Subjects in this arm will receive bilateral middle meningeal artery embolization with coils plus conventional standard pharmacotherapy for migraine.",[62,63],{"label":69,"type":70,"description":71,"interventionNames":72},"Conventional Standard Pharmacotherapy","ACTIVE_COMPARATOR","Subjects in this arm will receive only conventional standard pharmacotherapy for migraine, without any middle meningeal artery embolization intervention.",[63],[74,79],{"type":75,"name":76,"description":77,"armGroupLabels":78,"otherNames":44},"PROCEDURE","Middle meningeal artery embolization","Middle meningeal artery embolization with coils.",[65,58],{"type":80,"name":81,"description":81,"armGroupLabels":82,"otherNames":44},"DRUG","Conventional standard pharmacotherapy for migraine",[65,69,58],[84],{"name":85,"affiliation":5,"role":86},"Zeguang Ren, MD. PhD.","STUDY_CHAIR",[88,92],{"name":85,"role":89,"phone":90,"phoneExt":44,"email":91},"CONTACT","+86 0851-86770232.","renzem@gmail.com",{"name":93,"role":89,"phone":94,"phoneExt":44,"email":95},"Junshuan Cui, MD.","+8615761600325","junshuan2306@163.com",{"type":97,"investigatorFullName":98,"investigatorTitle":99,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"PRINCIPAL_INVESTIGATOR","Zeguang Ren","Professor, principle investigator, Department of Neurosurgery",[101,104,106],{"name":102,"class":103},"Sichuan Action Medical Technology Co., Ltd.","UNKNOWN",{"name":105,"class":103},"Juhui Medical Technology (Shenzhen) Co., Ltd.",{"name":107,"class":103},"Beijing Xinke Medical Technology Co., Ltd.","100642972",false,"NCT07633067","Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.","Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine: A Multicenter, Prospective, Double-blind, Multigroup, Randomized Controlled Trial.","FAST-EM-2","Inclusion Criteria:\n\n1. Age 18\\~80 years old (inclusive), regardless of gender.\n2. Voluntary written informed consent.\n3. Migraine diagnosed by neurologists\u002Fpain specialists according to the current International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria for migraine with or without aura.\n4. Migraine attack frequency of no less than 4 days per month within one month prior to enrollment.\n5. History of pharmacotherapy for migraine prophylaxis or treatment for at least 6 months.\n\nExclusion Criteria:\n\n1. Findings on cerebral angiography indicating secondary headache due to intracranial vascular disorders, including dural arteriovenous fistula, arteriovenous malformation, venous malformation, or other relevant cerebrovascular lesions; Moyamoya disease; or high-risk vascular anatomical variants unsuitable for safe vascular access or contraindicating MMA embolization.\n2. Complicated with cervical spondylosis and secondary headache of otogenic, rhinogenic, odontogenic origin; patients with a history of trigeminal autonomic cephalalgias; headache with other definite etiologies or secondary headache;\n3. Imaging diagnosis shows acute or chronic subdural hematoma, other acute intracranial lesions and other space-occupying lesions;\n4. Patients planning to undergo surgery within 90 days;\n5. Patients with a life expectancy of less than 12 months;\n6. Patients with a definite history of contrast media allergy;\n7. Patients with a history of opioid addiction;\n8. Breastfeeding or pregnant women, or patients with fertility plans within half a year;\n9. Subjects who participated in other clinical trials of drugs or medical devices before enrollment and did not reach the time limit of the primary study endpoint;\n10. Unable to understand headache-related assessment data such as headache diaries and requiring assistance from others to complete them;\n11. Patients with poor compliance judged by the investigator and unable to complete the study as required;\n12. Patients with a definite history of allergy to embolization materials such as nitinol alloy and\u002For cobalt-based alloy, platinum-tungsten alloy, etc.;\n13. Subjects with other comorbidities that restrict their participation in the study, prevent compliance with follow-up, or affect the scientific integrity of the study;\n14. Other conditions in which the investigator considers the patient inappropriate to participate in this study.","ALL","18 Years","80 Years",{"count":119,"type":120},150,"ESTIMATED","INTERVENTIONAL",[123],"NA","This study is a multicenter, prospective, double-blind, multi-arm, randomized controlled trial that investigates whether middle meningeal artery embolization is superior to current standard pharmacotherapy for migraine. The main objectives of the study are to explore whether middle meningeal artery embolization can reduce migraine patients' dependence on migraine medications and to assess the safety of middle meningeal artery embolization with coils.",[126],"Migraine",[126,128,129],"Middle meningeal artery","Embolization","NOT_YET_RECRUITING","2026-06-05",{"date":133,"type":134},"2026-06-08","ACTUAL",{"date":136,"type":120},"2026-06-15",{"date":138,"type":120},"2028-12-31",{"name":5,"class":6}]